For the Inventor, By the Inventor

Enter assignee name

Takara Bio Inc.

USPTO Granted Patents = 150

% Expired Patents = 64.0

CIPO Patents = 2

EPO Patents = 41

Trademarks = 17

Forward Citations = 488

Loading Chart...

Loading Chart...

237 inventors (with patents filed for the assignee):

Ikunoshin Kato (85 out of 210 patents)

Takashi Uemori (33 out of 44 patents)

Junichi Mineno (29 out of 29 patents)

4. Hiroaki Sagawa (27 out of 45 patents)

5. Kiyozo Asada (22 out of 47 patents)

6. Tatsuji Enoki (21 out of 33 patents)

7. Hiroyuki Mukai (20 out of 29 patents)

8. Hiroshi Shiku (12 out of 24 patents)

9. Hikaru Takakura (12 out of 15 patents)

10. Takeshi Sakai (11 out of 51 patents)

11. Hideto Chono (10 out of 13 patents)

12. Nobuto Koyama (10 out of 37 patents)

13. Eiji Kobayashi (9 out of 36 patents)

14. Yoshimi Sato (9 out of 12 patents)

15. Jun Tomono (9 out of 14 patents)

Core Competencies:

Nucleic Acid

AAV Variant

DNA Polymerase

Stem Cell Production

Chimeric Antigen Receptor

Endonuclease

RNA Detection

Cytotoxic T Lymphocyte

Gene Transfer

Viral Particles

Pluripotent Stem Cells

Nucleic Acid Amplification

150 patents: Sort by Forward Citations

1. 12673097 - IMPROVED DNA VACCINE FOR SARS-COV-2 (2026-07-07),

2. 12606845 - METHOD FOR PRODUCING NUCLEIC ACID-ENCAPSULATED AAV HOLLOW PARTICLE (2026-04-21),

3. 12480132 - HEAT RESISTANT MISMATCH ENDONUCLEASE VARIANT (2025-11-25),

4. 12421526 - AAV mutant having brain-targeting property (2025-09-23),

5. 12359177 - DNA polymerase mutant suited to nucleic acid amplification from RNA (2025-07-15),

6. 12018294 - DNA polymerase mutant suited to nucleic acid amplification from RNA (2024-06-25),

7. 12018276 - Lymphocyte production method (2024-06-25),

8. 11999972 - Fibronectin fragment to be used for stem cell production (2024-06-04),

9. 11572580 - Oligonucleotide preservation method (2023-02-07),

10. 11473057 - Method for obtaining microglia from pluripotent stem cells (2022-10-18),

11. 11225643 - Method for producing endothelial cells (2022-01-18),

12. 11220677 - Heat-resistant reverse transcriptase mutant (2022-01-11),

13. 11046939 - DNA polymerase variant (2021-06-29),

14. 11028131 - Mutant of adeno-associated virus (AAV) capsid protein (2021-06-08),

15. 10975415 - Methods of utilizing thermostable mismatch endonuclease (2021-04-13),

Takara Bio Inc., headquartered in Shiga, Japan, specializes in nucleic acid technology, focusing on the development and manufacturing of innovative solutions for genetic research and biotechnology applications. The company is known for its expertise in areas such as DNA polymerase, AAV variants, and stem cell production, contributing significantly to advancements in gene therapy and molecular biology. Takara Bio also engages in the production of tools for RNA detection and the development of chimeric antigen receptors, enhancing the capabilities of cytotoxic T lymphocytes in therapeutic contexts.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

150 Patents

#3 in Shiga

#856 in Japan

#5,434 in the World

Takara Bio Inc.

Forward Citations = 488

237 inventors:

Ikunoshin Kato (85 out of 210 patents)

Takashi Uemori (33 out of 44 patents)

Junichi Mineno (29 out of 29 patents)

4. Hiroaki Sagawa (27 out of 45 patents)

5. Kiyozo Asada (22 out of 47 patents)

Please report any incorrect information to [email protected]

Loading…